Research programme: thrombopoietin receptor agonists - Chugai
Alternative Names: huVB22B; Thrombopoietin receptor agonists research programme - ChugaiLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Chugai Pharmaceutical
- Class Antibodies; Small molecules
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in Japan
- 09 Dec 2008 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Thrombocytopenia presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
- 09 Feb 2005 Preclinical trials in Thrombocytopenia in Japan (unspecified route)